Summary:
- The article presents the results from the primary analysis of the Phase 3 SPLASH trial, which evaluated Lantheus' PSMA-targeted therapy in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
- The SPLASH trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) for patients treated with the PSMA-targeted therapy compared to those receiving standard of care.
- The results were presented at the 2024 European Society for Medical Oncology (ESMO) Congress, highlighting the potential of this PSMA-targeted therapy to address the unmet needs of patients with mCRPC.